Personalized oncology is changing the cancer treatment landscape. Increasingly, patients are treated according to the distinct genetics of their tumors. To realize the full benefits of this shift, cancer patients and advocates must be engaged and informed. Cancer Commons has joined the Personalized Medicine World Conference (PMWC) to co-host a special two-day track for cancer patients and advocates. Attendees will have the opportunity to discuss personalized medicine with each other and with researchers, clinicians, and industry leaders. Distinguished speakers will present the latest advances in personalized oncology and discuss its promise for the future.

PMWC is the largest and most established global conference on personalized medicine. It provides a platform for clinical, scientific, industry, and mobile health stakeholders to collaborate and catalyze further change. Cancer patients and advocates can register for thePatient & Advocate Program (Track 4) at a discounted fee.

PMWC 2014 will take place January 27-28, 2014, at the Computer History Museum in Mountain View, CA.

Cancer Commons founder Marty Tenenbaum will lead a panel discussion at the 2014 Personalized Medicine World Conference (PMWC) on Jan 27. The discussion, entitled, “PM in Oncology Today: Making It Work for Patients, Clinicians, Researchers, and Industry,” will also feature George Demetri of Dana-Farber/Harvard Cancer Center, Vincent A. Miller of Foundation Medicine, lung cancer survivor Neil Schiffman, and Edgar Staren of CTCA Medicine and Science. Their diverse perspectives will ignite insightful discussion regarding the current use and future promise of personalized medicine in cancer.

The 6th annual PMWC conference in Silicon Valley runs Jan 27–28. It brings together leaders from multiple sectors—including business, government, healthcare-delivery, research and technology—to learn from each other and further the field of personalized medicine. Dr. Tenenbaum’s panel discussion is at 11 am on the main-stage. General registration is available through Jan 24.

Cancer Commons founder Dr. Marty Tenenbaum spoke at the monthly meeting of Silicom Ventures, a Silicon Valley-based investment forum. Dr. Tenenbaum discussed his vision for a personalized approach to oncology, offering solutions that could help answer these questions:

-Which are the best drugs and trials for me?
-How can I get timely and affordable access to the latest investigational drugs?
-How can we slash the time and cost of drug development so that the economics work for therapies that target small subsets of patients?
-Can cancer research be funded, one patient at a time?

For more information on this specific event, see Silicom Ventures

To view this presentation, see How To Beat Cancer

Dr. Tenenbaum described opportunities to apply human and machine intelligence to organize and refine the world’s knowledge about treating cancer. The talk discussed AI topics for medicine including text mining, machine learning, crowdsourcing and others. He also gave an update on his work with Cancer Commons.

To view the presentation see How to Beat Cancer HIAI July 2013

Allan will be attending the UNESCO 11th International Conference on Privacy, Security and Trust (PST2013) in Tarragona, Catalonia, July 10-12.  He will be presenting the paper authored with Fellow Jeff Shrager and 2012 Intern Alegria Baquero titled Blend me in: Privacy-Preserving Input Generalization for Personalized Online Services (slidespaper).

Personalized Oncology – Fulfilling the Promise for Today’s Patients

In honor of the 20th anniversary of the Molecular Medicine Tri-Conference, CHI and Cancer Commons presented a plenary panel on Personalized Oncology. Innovations such as NGS and The Cancer Genome Atlas have revealed that cancer comprises hundreds of distinct molecular diseases. Early clinical successes with targeted therapies suggest that cancer might one day be managed as a chronic disease using an evolving cocktail of drugs. Representing all five conference channels, Diagnostics, Therapeutics, Clinical, Informatics, and Cancer, a panel of experts led a highly interactive exploration of what it will take to realize this vision in the near future.

For more details, see the Cancer Commons website.

To view the presentation, see TriCon 2 13 13 Deck

Dr. Tenenbaum, Founder and Chairman of Cancer Commons, speaks at the Institute of Medicine’s Sharing Clinical Research Data:  An Institute of Medicine Workshop, October 4-5, 2012 at the National Academy of Sciences Building in Washington DC.

The workshop is being jointly organized by the Institute of Medicine’s Forum on Drug Discovery, Development, and Translation; Forum on Neuroscience and Nervous System Disorders; National Cancer Policy Forum; and Roundtable on Translating Genomic-Based Research for Health.

Additional information can be found at The Institute of Medicine.

Sarah Greene, Executive Director at Cancer Commons, speaks at the Open Science Summit in Mountain View, California on Saturday, October 20, 2012.   Ms. Greene discusses Cancer Commons Rapid Learning Community.

To view her talk,  jump to the 27:02 mark.

Dr. Tenenbaum, Founder and Chairman of Cancer Commons, will speak at the Personalized Medicine World Conference on January 29, 2013.


CHI and Cancer Commons will present a plenary panel on Personalized Oncology at the Molecular Medicine Tri-Conference,  February 11 – 14, 2013, at Moscone North Convention Center, San Francisco.

The plenary, “Personalized Oncology – Fulfilling the Promise for Today’s Patients”,  will be on Wednesday, February 13, from 8 am – 9:40 am.

For additional information regarding the plenary, see the conference preview.

For more details, see the Cancer Commons website.